Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Monday 18 March, 2019

GlaxoSmithKline PLC

GSK Annual Report 2018 on Form 20-F

RNS Number : 0917T
GlaxoSmithKline PLC
15 March 2019

Issued: 15 March 2019, London UK - LSE Announcement


GlaxoSmithKline plc
Annual Report 2018 on Form 20-F


In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 15 March 2019 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2018. GSK's 2018 Annual Report on Form 20-F is available online at GSK's website at and also online at

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on

A hard copy version of the GSK 2018 Annual Report, together with the Annual Summary and Notice of Annual General Meeting will be available on or about 2 April 2019.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2018, free of charge, by either:

(i)      writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii)      writing to The Bank of New York Mellon, our ADR depositary in the US, at the following address: BNY Mellon Shareowner Services, PO Box 505000, Louisville, KY 40233-5000, or by telephone on +1 877 353 1154 (US toll free) or +1 201 680 6825 (outside the US); or

(iii)     contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).


Victoria Whyte
Company Secretary
15 March 2019


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2018.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t